The global antiplatelet market is anticipated to grow rapidly during the forecast period. The major drivers for antiplatelet market are factors such as the proliferation of antithrombotic/anticoagulant drugs, increasing aging population, an increase in thrombotic events, and recent advances in pharmaceuticals.
An antithrombotic agent is a drug that reduces the formation of blood clots. Antithrombotic could be used therapeutically for prevention (primary prevention, secondary prevention) or treatment of a dangerous blood clot (Acute thrombus).
Antithrombotic is a drug that helps reduce thrombus formation. Different antithrombotic affect different blood clotting processes like antiplatelet drugs, anticoagulants, and thrombolytic drugs. Its main application is to treat the abnormal blood flow in the human body.
The major causes of thrombosis are inactivity, blood vessel damage, medical and genetic conditions, pregnancy, obesity, and smoking. With the growing population across the globe, the demand for such life savings drugs is bound to increase.
An antiplatelet drug is a member of a class of pharmaceuticals that decrease platelet aggregation and inhibit thrombus formation. They are effective in the arterial circulation. They are widely used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
Antithrombotic drugs, which include anticoagulants, antiplatelate drugs, and thrombolytic drugs, are used in wide range of indication for the prevention and treatment of ischemic events. These include acute coronary syndrome (ACS), myocardial infarction (MI), and stroke, venous thromboembolism (VTE) and peripheral occlusion (PAO).
Antiplatelet Market is segmented on the basis of different blood clot processes as follows:
Antiplatelet drugs- They limit the migration or aggregation of platelets. Antiplatelet drug decreases the ability of blood clot to form by interfering with platelet activation process in primary homeostasis. Antiplatelet drugs can reversibly or irreversibly inhibit the process involved in platelet activation resulting in decreased tendency of platelets to adhere to one another and damaged blood vessels endothelium.
Oral antiplatelet drugs account for most long-term prevention prescriptions, as the most widely used oral anticoagulant, warfarin, is plagued with drug and food-drug interaction, and confined to the hospital setting.
Anticoagulants- They limit the ability of the blood to clot. “Anticoagulants” is a class of drug that works to prevent blood coagulation. Such substances occur naturally in leeches and blood-sucking insects. Some anticoagulants are used in medical equipment, such as test tubes, blood transfusion bags, and renal dialysis equipment.
Anticoagulants are closely related to ant platelet drugs and thrombolytic drugs by manipulating the various pathways of blood coagulation. Specifically, anticoagulants manipulate the coagulation cascade that builds upon the initial platelet thrombus.
Thrombolytic drugs- They act to dissolve clots after they have formed. Thrombolytic drugs are used in medicine to dissolve blood clots in procedure termed as “thrombolysis”. They limit the damage caused by the blockage or occlusion of a blood vessel
Thrombolytic agents can be differentiated from fibronolytic agents as they dissolve the fibrin only while thrombolysis refers to the dissolution of the entire thrombus.
Antithrombotics market is segmented on the basis of drugs are as follows:
Antiplatelet Drugs: Glycoprotein IIb/IIIa inhibitors, Abciximab, Eptifibatide; Anticoagulant drugs: Factor Xa inhibitors (with some II inhibition), Heparin group/ glycosaminoglycans (bind antithrombin) Low molecular weight heparin (Bemiparin, certoparin), Thrmbolytic drugs/fibrinolytics: Plasminogen activators: r-tPA (Alteplase. Reteplase. Tenecteplase)
Antithrombotics market is segmented on the basis of Geographical Region into North America, Europe, Asia Pacific, Middle East and Africa, Latin America.
The antiplatelet market major players are as follows: Abbott Laboratories, Armetheon Inc., Astrazeneca, Baxter International, Bayer AG, Biovascular Inc., Boehringer Ingelheim Gmbh, Bristol-Myers Squibb Co., CSL Behring, Daiichi Sankyo Co. Ltd., Eli Lilly, Emisphere Technologies, F.Hoffmann-La Roche AG, Genentech, Glaxosmithkline, Johnson & Johnson, Ligand Pharmaceuticals Inc., The Medicines Co., Merck, Merrion Pharmaceuticals Ltd., Microbix Biosystems Inc., Novartis,ONO Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.